RCT1100 not checked

ReCode Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer”In the company’s words, NCT05737485 on ClinicalTrials.gov
Tested for
Primary Ciliary Dyskinesia (2 trials), Primary Ciliary Dyskinesia (PCD)
Main trialPhase 1
“This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.”In the company’s words, NCT05737485 on ClinicalTrials.gov

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Completed 25 Jul 2024 Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
Phase 1Completed 6 Jun 2025 A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD
Phase 1Completed 30 Jun 2025 Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RCT1100

Following is part of Solo: you see every change to RCT1100 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in